Nkarta, Inc.
Financials
Valuation Metrics
Nkarta, Inc.'s Market Cap is $202M. At end of 2025 it was $137M. Ranked #3025 of 3,121 in US market (top 97%), #1388 of 1,463 on NASDAQ (top 95%), #253 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 95%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $202M | US#3,025/3,121 Sec#253/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-117M | US—/3,121 Sec—/266 |
| Total Assets | $338M | US#2,889/3,121 Sec#201/266 |
| Net Assets | $248M | US#2,602/3,121 Sec#170/266 |
| Employees | 106 | US#2,615/3,121 Sec#174/266 |
| Value | ||
| P/B | 0.82x | US#225/3,121 Sec#7/266 |
| FCF Yield | -46.38% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -47.36% | US#2,668/3,121 Sec#152/266 |
| ROA | -34.75% | US#2,919/3,121 Sec#172/266 |
| Financial Health | ||
| Debt Ratio | 36.29% | US#415/3,121 Sec#121/266 |
| Total Debt | $74M | US#2,522/3,121 Sec#136/266 |
| FCF | $-94M | US#2,621/3,121 Sec#138/266 |
| Cash | $25M | US#2,814/3,121 Sec#251/266 |
| Current Ratio | 7.98x | US#320/3,121 Sec#99/266 |
| Performance | ||
| 1Y Return | 42.21% | US#606/3,121 Sec#113/266 |
| 1M Return | 11.42% | US#123/3,121 Sec#13/266 |
| From 52W High | -23.92% | US#1,764/3,121 Sec#134/266 |
| 1Y MDD | -43.05% | US#2,162/3,121 Sec#153/266 |
| Trading | ||
| Volume | 571,190 shares | US#2,005/3,121 Sec#211/266 |
| Trading Value | $2M | US#2,964/3,121 Sec#254/266 |
| Per Share | ||
| EPS | $-1.64 | US—/3,121 Sec—/266 |
| BPS | $3.46 | US#2,428/3,121 Sec#156/266 |
Company Info
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.